CunninghamD.: Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failire for patients with metastatic colorectal cancer.Lancet352: 1413, 1998.
2.
RougierP.: Randomized trial of irinotecan versus fluorouracil by continous infusion after fluorouracil failure in patients with metastatic colon cancer.Lancet352: 1407, 1998.
3.
DuillardJ.Y.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial.Lancet355: 1041, 2000.
4.
SaltzL.B.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.N Engl J Med343: 905, 2000.
5.
De GramontA.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.J Clin Oncol18: 2939, 2000.
6.
TournigandC.: FOLFIRI followed by FOLFOX versus FOLFOX followed by FOLFIRI in metastatic colorectal cancer: final results of a randomised trial.Proc ASCO20: 494 (abst), 2001.
7.
Ben AyedF.: CPT-11 combined or alternating with 5-fluorouracil/folinic acid in advanced colorectal cancer.Proc ASCO20: 536 (abst), 2001.
8.
LabiancaR.: CPT-11 alternated with leucovorin + fluorouracil in advanced colorectal cancer. A multicentric randomised phase II trial.Proc ASCO20: 535 (abst), 2001.
9.
CorneliaP.: Biweekly irinotecan plus levo-leucovorin-modulated 5FU bolus in advanced colorectal carcinoma: a SICOG randomised trial.Proc ASCO20: 537 (abst), 2001.
10.
DucreuxM.: Phase II study of high-dose irinotecan combined with 5-fluorouracil/folinic acid in 1st line metastatic colorectal cancer.Proc ASCO20: 2210 (abst), 2001.
11.
KemenyN.E.: Phase I/II trial weekly oxaliplatin and irinotecan in previously treated patients with metastatic colorectal cancer.Proc ASCO20: 529 (abst), 2001.
12.
ScheithauerW.: Combined irinotecan and oxaliplatin plus granocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.J Clin Oncol17: 902, 1999.
13.
GoldwasserF.: Dose escalation of CTP-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.Ann Oncol11: 1463, 2000.
14.
WassermanE.: Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.J Clin Oncol17: 1751, 1999.
15.
SaltzL.: Cetuximab plus irinotecan is active in CPT-11-refractory colorectal cancer that expresses epidermal growth factor receptor.Proc ASCO20: 7 (abst), 2001.
16.
GovindarajanR.: Irinotecan and thalidomide in metastatic colorectal cancer.Oncology14(suppl 12): 29, 2000.
17.
GovindarajanR.: Irinotecan and thalidomide in metastatic colorectal cancer: preliminary results of a phase II study.Proc ASCO20: 2191 (abst), 2001.
18.
VanhoeferU.: Final results of a randomised phase III trial of sequential high-dose methotrexate, fluorouracil and doxorubicin versus etoposide, leucovorin and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer, Gastrointestinal Tract Cancer Cooperative Group.J Clin Oncol18: 2648, 2000.
19.
KambeM.: A late phase II study of irinotecan in patients with advanced gastric cancer.Proc ASCO12: 198 (abst), 1993.
20.
BokuN.: Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.J Clin Oncol17: 319, 1999.
21.
ShiraoK.: Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.J Clin Oncol15: 921, 1997.
22.
De VoreR.F.: Phase II study of irinotecan in patients with previously treated small-cell lung cancer.Proc ASCO17: 1736 (abst), 1998.
23.
Le ChevalierT.: A phase II study of irinotecan in patients with small-cell lung cancer progressing after initial response to first-line chemotherapy.Proc ASCO16: 1617 (abst), 1997.
24.
MasudaN.: CPT-11: a new derivate of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.J Clin Oncol10: 1225, 1992.
25.
NegoroS.: A phase II study of CPT-11, a camptothecin derivate, in patients with primary lung cancer.Gan to Kagaku Ryoho18: 1013, 1991.
26.
KudohS.: Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer.J Clin Oncol16: 1068, 1998.
27.
OkishioK.: A phase II study of irinotecan and cisplatin in previously treated small-cell lung cancer.Proc ASCO17: 1914 (abst), 1998.
28.
NodaK.: Randomized phase III study of irinotecan and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study 9511.Proc ASCO19: 1887 (abst), 2000.
